CLINICAL TRIAL
LETTER
Add like
Add dislike
Add to saved papers

Doxycycline for the treatment of cutaneous leishmaniasis.

The incidence of cutaneous leishmaniasis has shown a resurgence in recent years in Tunisia. Because of the toxicity and high cost of pentavalent antimonials we have sought alternative medications. In a study of 14 patients with cutaneous leishmaniasis, ten patients achieved complete clinical regression of the lesions with oral administration of doxycycline, 200mg per day, for 15-30 days.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app